News

Prolytix Honored as One of Vermont’s Best Places to Work 2025 Prolytix is excited to announce that we have been recognized as one of Vermont’s Best Places to Work 2025 —a distinction that underscores our deep commitment to cultivating a vibrant and innovative work environment. This honor comes after a thorough evaluation that examined our […]

The partnership focuses on enabling customer success, by reducing time-to-value and optimizing R&D investments with integrated solutions and processes. Halifax, NS and Essex Junction, VT, March 11, 2024 – Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. Together the partners

ESSEX JUNCTION, VT; March 3, 2022 – Haematologic Technologies (“HT”), a global analytical and bioanalytical leader for large molecule drug development, today announced they’ll be operating under the new name, Prolytix — integrating HT and Haemtech Biopharma Services. This integration is bringing biotherapeutic, analytical CMC, and bioanalytical CRO services, expertise, and facilities together to support

John Strokis to Lead the Quality Initiatives for the Company Through Next Phase of Growth ESSEX JUNCTION, Vt., Dec. 16, 2021 /PRNewswire/ — Haematologic Technologies (“HT”), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of John Strokis as Vice President, Quality. John will lead quality initiatives through the next phase of the Company’s growth,

David Sunseri, Ph.D. to Lead the Company Through Next Phase of Growth March 1, 2021 – Essex Junction, VT:  Haematologic Technologies (“HTI”), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of David Sunseri, Ph.D. as President and Chief Executive Officer. David will lead the next phase of the Company’s growth,

Expanded Capabilities add to HTI’s Growing Large Molecule Bioanalysis Services Business September 30th, 2020 Essex Junction, VT –Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today announced the addition of a High Resolution Mass Spectrometry (HRMS) lab headed by Kevin

Greiner Bio-One and Haematologic Technologies Announce a Collaboration to Provide Complete Development and Manufacturing of Customized Blood Collection Tubes in Support of New IVDs, Clinical Diagnostics, and Large Volume Production MONROE, N.C. and ESSEX JCT., Vt., Aug. 20, 2020 /PRNewswire/ — Greiner Bio-One and Haematologic Technologies (HTI) are pleased to announce a collaboration to provide

Dear Customer: As an entrusted partner and service provider to you and your company, we would like to assure you that HTI is taking precautions not only to maintain business continuity, but also to ensure the safety and well being of our staff and our clients. To ensure that we are able to provide uninterrupted

Joint News Release HTI Media Contact:Robert Myers, VP of Business DevelopmentTel.: (802) 878-1777Email: [email protected] Edgewater Media Contact:Robert Girton, PartnerTel.: (216) 292-3858Email: [email protected] Edgewater Capital Partners to Acquire Haematologic Technologies Essex Junction, VT and Cleveland, OH, October 11, 2019 – Edgewater Capital Partners announced today that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a

When evaluating drug candidates that treat hemostasis directly, or those that have potential off-target coagulation effects, understanding their impact on blood coagulation is essential. Several assays can measure a drug candidate’s impact on hemostasis by evaluating patient plasma samples throughout the clinical trial process. Using this information, drug manufacturers can increase the safety of their